0001209191-21-032978.txt : 20210514 0001209191-21-032978.hdr.sgml : 20210514 20210514201211 ACCESSION NUMBER: 0001209191-21-032978 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210512 FILED AS OF DATE: 20210514 DATE AS OF CHANGE: 20210514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLACIK CHARLES P CENTRAL INDEX KEY: 0001204660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 21927013 MAIL ADDRESS: STREET 1: 250 S. KRAEMER BLVD CITY: BREA STATE: CA ZIP: 92821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8585521100 MAIL ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-12 0 0000353569 QUIDEL CORP /DE/ QDEL 0001204660 SLACIK CHARLES P 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 1 0 0 0 Common Stock 2021-05-12 4 M 0 1040 0.00 A 12255 D Common Stock 2021-05-12 4 M 0 191 0.00 A 12446 D Common Stock 2021-05-12 4 M 0 19 0.00 A 12465 D Common Stock 2021-05-13 4 S 0 1000 113.258 D 11465 D Common Stock 2021-05-14 4 M 0 612 0.00 A 12077 D Common Stock 2021-05-14 4 M 0 122 0.00 A 12199 D Restricted Stock Units 2021-05-12 4 M 0 1040 0.00 D 2021-05-12 2021-05-12 Common Stock 1040 0 D Restricted Stock Units (Converted) 2021-05-12 4 M 0 191 0.00 D Common Stock 191 0 D Restricted Stock Units (Premium) 2021-05-12 4 M 0 19 0.00 D Common Stock 19 0 D Restricted Stock Units (Converted) 2021-05-14 4 M 0 612 0.00 D Common Stock 612 0 D Restricted Stock Units (Premium) 2021-05-14 4 M 0 122 0.00 D Common Stock 122 0 D Reflects release of restricted stock units that were previously reported on Form 4. The weighted average sale price for these transactions was $113.258 per share, with a range of $112.62 to $120.00. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. Restricted stock units convert into common stock on a one-for-one basis. Shares vested and released on the transaction date pursuant to Issuer's deferred compensation plan. Robert J. Bujarski, attorney-in-fact for Charles P. Slacik 2021-05-14